Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare use of a tissue-engineered bone to use of a standard allograft bone to treat bone defect in patients. The hypothesis is that use of the tissue-engineered bone is effective and safe to treat the bone defect in patients.


Clinical Trial Description

Patients with the bone defect without infection and sever system diseases will be recruited.

The material selected as the scaffold for this study will be a porous β-tricalcium phosphate scaffold (β-TCP) scaffold and scaffold is custom-made according to the size and shape of bone defect after three-dimensional CT scan. Human BMSCs will be obtained and cultured before operation and 3.4×106 cells in 10ml serum-free medium will be seeded onto scaffold to construct the tissue engineered bone graft and co-cultured for two weeks.

The implant operation will be carried out under the general anesthesia. The tissue engineered bone graft will be implanted into the bone defect area. The bone defect area will be covered with surrounding soft tissue and muscle to close the wound. Anti-inflammatory, repercussive and analgesic drugs will be used for 1 week.

Patient will be hospitalized for 1 to 2 weeks after surgery. Blood routine examination, erythrocyte sedimentation rate, immunoglobulin, autoantibodies and clinical examination will be carried out for signs of pain, swelling, immune rejection and infection. Patient will be evaluated at 3 days,3, 6, 12, 18 and 22 months after operation by radiography; Three-dimensional CT scan will be also performed at regular intervals. The function of the body will be evaluated at regular intervals. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02748343
Study type Interventional
Source Xijing Hospital
Contact long bi, MD,PHD
Phone +86 02984773524
Email bilong@fmmu.edu.cn
Status Recruiting
Phase Phase 1/Phase 2
Start date November 2014
Completion date December 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02815423 - Safety and Exploratory Efficacy Study of UCMSCs in Patients With Fracture and Bone Nonunion Phase 1/Phase 2
Recruiting NCT04997590 - Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Healing N/A